| # | Drug | Count |
|---|---|---|
| 0 | RITUXIMAB | 43 |
| 1 | CYCLOPHOSPHAMIDE | 41 |
| 2 | CYCLOPHOSPHAMIDE FOR INJECTION | 41 |
| 3 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 41 |
| 4 | DOXORUBICIN | 33 |
| 5 | PREDNISONE | 31 |
| 6 | PREDNISOLONE | 28 |
| 7 | PREDNISOLONE ORAL | 28 |
| 8 | PREDNISOLONE ORAL SOLUTION | 28 |
| 9 | RILPIVIRINE | 24 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | CABOTEGRAVIR SODIUM | 16 | 0.0100 |
| 1 | RILPIVIRINE | 24 | 0.0034 |
| 2 | MARAVIROC | 5 | 0.0022 |
| 3 | ENTECAVIR | 17 | 0.0014 |
| 4 | IBRITUMOMAB TIUXETAN | 2 | 0.0013 |
| 5 | ELBASVIR AND GRAZOPREVIR | 5 | 0.0012 |
| 6 | GLOFITAMAB | 3 | 0.0011 |
| 7 | ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE | 7 | 0.0011 |
| 8 | CABOTEGRAVIR | 9 | 0.0011 |
| 9 | TENOFOVIR DISOPROXIL FUMARATE TABLETS | 9 | 0.0010 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CCR5 Co-receptor Antagonist [EPC] | 5 | 0.0022 |
| 1 | CD38-directed Cytolytic Antibody [EPC] | 9 | 0.0015 |
| 2 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 3 | 0.0007 |
| 3 | Chemokine Receptor Type 4 Interaction [EPC] | 1 | 0.0007 |
| 4 | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 36 | 0.0007 |
| 5 | Interleukin-17 Receptor A Antagonist [EPC] | 1 | 0.0005 |
| 6 | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 37 | 0.0003 |
| 7 | Hepatitis C Virus NS3/4A Protease Inhibitor [EPC] | 5 | 0.0003 |
| 8 | Rifamycin Antimycobacterial [EPC] | 1 | 0.0003 |
| 9 | Alkylating Drug [EPC] | 45 | 0.0002 |